![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Emergent Drug Resistance from the HIV-1 Phase 3
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Studies through Week 96
|
|
|
Reported by Jules Levin
CROI 2013
K White*, ME Abram, R Kulkarni, M Rhee, J Szwarcberg, and MD Miller
Gilead Sciences, Inc., Foster City, CA, US
![CROI1.gif](../images/031513/031513-5/CROI1.gif)
![CROI2.gif](../images/031513/031513-5/CROI2.gif)
![CROI3.gif](../images/031513/031513-5/CROI3.gif)
![CROI4.gif](../images/031513/031513-5/CROI4.gif)
![CROI5.gif](../images/031513/031513-5/CROI5.gif)
![CROI6.gif](../images/031513/031513-5/CROI6.gif)
![CROI7.gif](../images/031513/031513-5/CROI7.gif)
![CROI8.gif](../images/031513/031513-5/CROI8.gif)
![CROI9.gif](../images/031513/031513-5/CROI9.gif)
![CROI10.gif](../images/031513/031513-5/CROI10.gif)
![CROI11.gif](../images/031513/031513-5/CROI11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|